Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Nuvectis reported expanded Phase 1b data for NXP200, a second-generation paradox-breaker BRAF inhibitor, showing a 40.0% ORR including 3 complete responses in high-grade BRAF V600-mutated recurrent/progressive gliomas. In low-grade glioma the ORR was 42.9% with one CR, and the disease control rate across all 27 efficacy-evaluable patients was 85.2%. Responses were deep (>80% tumor burden reduction in most responders) and included activity in patients previously treated with a BRAF inhibitor. Safety was manageable, with 14.3% of the 28 safety-evaluable patients experiencing Grade 3+ treatment-related adverse events and no treatment discontinuations or deaths.
Key figures
- Drug Name
- NXP200
- Phase Of Trial
- Phase 1b
- Disease control rate
- 85.2% (23/27)
- Grade3plus trae rate
- 14.3%
- Median os high grade
- 17.15 months
- Orr low grade glioma
- 42.9% (3/7)
- Median dor high grade
- 6.97 months
- Orr high grade glioma
- 40.0% (8/20)
- Complete responses total
- 4
- Efficacy evaluable patients
- 27
- Patients achieved tumor reduction
- 81.5% (22/27)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.